Cipla Ltd. News and Updates

Name: Latest research reports of Cipla Ltd. authored by Geojit BNP Paribas and published by - Trendlyne research reports.
Item: Cipla Ltd.
Rating: 5
Author: Geojit BNP Paribas

Keep track of all breaking news on Cipla Ltd. from all sources in a single place.

Load latest

Cipla Ltd.

06 Jan 2025

1508.65

1.08%

Cipla launches CipAir mobile app for first-line asthma screening in India

Business Standard

The app aims to assess users' likelihood for asthma, thereby enabling timely intervention and management

Cipla Ltd. is trading above its 100 day SMA of 1477.8

Cipla Ltd.

20 Dec 2024

1508.65

1.08%

GST authority imposes Rs 1 cr fine on Cipla for inadmissible credit claim

Business Standard

Pharma major Cipla Ltd on Friday said a fine of over Rs 1 crore has been imposed on the company by GST authority for alleged inadmissible credit claim. The company has received an order dated December 18, 2024 passed by the GST authority, imposing a penalty of Rs 1,11,94,324 under applicable provisions of the Central Goods and Services Tax Act, 2017, Cipla said in a regulatory filing. "The order has been passed by GST Authority on the contention that the company has availed inadmissible TRAN-1 credit. The GST Authority has ordered for recovery of the same along with applicable interest and penalty," it added. Cipa said based on assessment of facts and prevailing law, it is "of the view that the penalty levied is arbitrary and unjustified". "The company will file necessary appeals with the appellate authority in this regard. There is no material impact on the company's financials or operations due to the said order," it added.

Cipla Ltd. is trading above its 100 day SMA of 1477.8

Cipla Ltd.

17 Dec 2024, 10:47AM

1508.65

1.08%

Cipla shares rise over 2% as Kotak forecasts better days ahead, upgrades rating to buy'

Economic Times

Cipla shares rose by 2.4% to Rs 1,483.40 on Tuesday after Kotak Institutional Equities upgraded the stock from "add" to "buy," with a target price of Rs 1,725. This suggests a potential upside of over 16% from the current levels.

Cipla Ltd. has an average target of 1707.30 from 11 brokers.

Cipla shares gain; Kotak upgrades stock to 'Buy' from 'Add'; check target

Business Standard | 17 Dec 2024, 10:34AM

Cipla Ltd.

12 Dec 2024

1508.65

1.08%

Cipla's inhaled insulin' from US' MannKind Corp adds a layer of convenience' for those with diabetes

Business Line

Recently, India's Central Drugs Standard Control Organisation gave Cipla the approval to exclusively distribute and market Afrezza (human insulin) inhalation powder in India

Number of FII/FPI investors decreased from 1132 to 1077 in Dec 2024 qtr

HSBC bullish on Indian pharma stocks for 2025

Economic Times | 12 Dec 2024 1 more

Cipla Ltd.

11 Dec 2024

1508.65

1.08%

Cipla to bring in inhaled insulin Afreeza from US' MannKind Corporation

Business Line

The Central Drugs Standard Control Organisation (CDSCO) has given Cipla the approval to exclusively distribute and market Afrezza (human insulin) inhalation powder, in India

Cipla Ltd. has an average target of 1707.30 from 11 brokers.

Cipla gets approval to market Afrezza insulin inhalation powder in India

Business Standard | 11 Dec 2024

Cipla Ltd.

04 Dec 2024

1508.65

1.08%

CIPLA LTD

Buy: Cipla Ltd.

Target

Geojit BNP Paribas

Cipla Ltd. is trading below its 150 day SMA of 1523.2

Cipla Ltd.

02 Dec 2024

1508.65

1.08%

Cipla Promoters Sell 1.72% Stake For Over Rs 2,000 Crore

NDTV Profit

The promoter group held a 31.66% stake in the Mumbai-headquartered company before the sale of equity, while after it, their cumulative holding was reduced to 29.94%.

Cipla Ltd. has an average target of 1707.30 from 11 brokers.

Cipla receives unsolicited ESG rating of B+ from SES Research

Business Line | 02 Dec 2024 1 more

Cipla Ltd.

29 Nov 2024

1508.65

1.08%

Cipla promoters may sell 1.72% stake worth Rs 2,000 crore via block deal

Business Standard

The floor price for the Cipla share sale has been set at Rs 1,442 per share, reflecting a 6 per cent discount to the current market price

Cipla Ltd. is trading below its 150 day SMA of 1523.2

Cipla promoters to sell 1.72% stake in likely block deal worth Rs 2,000 crore: Report

Economic Times | 29 Nov 2024 1 more

Cipla Ltd.

28 Nov 2024

1508.65

1.08%

CIPLA LTD.

Buy: Cipla Ltd.

Recommendation Target

Prabhudas Lilladhar

Cipla Ltd. is trading above its 100 day SMA of 1477.8

Cipla Ltd.

13 Nov 2024

1508.65

1.08%

Drug maker Cipla gets 8 observations from USFDA for Bengaluru facility

Business Standard

Drug maker Cipla on Wednesday said the US health regulator has issued eight observations after inspecting its Bengaluru-based plant. The US Food and Drugs Administration (USFDA) conducted an inspection at the company's manufacturing facility in Virgonagar, Bengaluru from November 7- 13, the Mumbai-based based drug maker said in a filing to BSE. On conclusion of the inspection, the company received eight observations in Form 483, it added. The company said it will work closely with the USFDA and remain committed to addressing these observations comprehensively within stipulated time.